Cancer Therapy Using a Targeted Magnetoliposomes Encapsulated Doxorubicin Assisted Ultrasound. (3rd July 2022)

• Record Type: Journal Article
• Authors: Ansari, Mojtaba; Eslami, Hossein; Javadpour, Sirus; Yousefi, Elham
• Is Part Of: Materials technology. Volume 37:Number 8(2022)
• Page Start: 858
• Page End: 865
• Publication Date: 2022-07-03
• Subjects: Magnetoliposomes -- sonodynamic therapy -- doxorubicin -- breast cancer -- cell viability; Materials -- Periodicals; Materials science -- Periodicals; Materials -- Technological innovations -- Periodicals; 620.1105
• DOI: 10.1080/10667857.2021.1903136
• Languages: English
• ISSNs: 1066-7857

Abstract

ABSTRACT: Biodistribution and tumour agglomeration of chemotherapeutic drugs are improved by nanoparticles augmenting the ratio of efficacy and toxicity. Iron oxide nanoparticles have attracted growing attention in diagnosis, cancer therapy, and smart drug delivery. To simplify the combined therapy and targeting drug delivery such as using ultrasound, we developed magnetoliposome-encapsulated doxorubicin. Superparamagnetic iron oxide nanoparticles and magnetoliposome-encapsulated doxorubicin were well synthesised without any remarkable mitigation of the saturation magnetisation. Doxorubicin and the synthesised iron oxide nanoparticles were passively encapsulated into PEGylated liposomes leading to stable soluble magnetoliposomes with a size of about 485 nm. The cytotoxicity of doxorubicin-loaded magnetoliposomes was examined on MCF-7 cells. Compared with chemotherapy alone, the combined therapy employing ultrasound showed a synergistic effect, giving rise to more robust cytotoxicity and higher therapeutic efficacy. Hence, the multifunctional doxorubicin-loaded magnetoliposomes permit them to selectively deliver a combinatorial therapeutic load with increased therapeutic effectiveness.